Needham & Company and Cantor Fitzgerald raised price objectives and issued buy ratings for Annexon, with MarketBeat reporting consensus data.
4 reports, 1 independent
Updated Sep 12
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Needham & Company and Cantor Fitzgerald raised price objectives and issued buy ratings for Annexon, with MarketBeat reporting consensus data.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Needham & Company
American independent investment bank and asset management firm
-
Cantor Fitzgerald
American financial services company
-
MarketBeat
American personal finance blog
Related events
- TD Cowen and Needham & Company boosted the price target and gave a 'buy' rating for Ultra Clean.
- Cantor Fitzgerald and Jefferies Financial Group raised price targets and gave 'buy' ratings on UnitedHealth Group stock.
- MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.
- MarketBeat provided average ratings and consensus target prices for Pacira BioSciences, while Needham and Royal Bank of Canada issued rating updates.
- Avalo Therapeutics received multiple rating changes and analyst coverage from firms including Cantor Fitzgerald, Bank of America, and Weiss Ratings.